How EHR partner programs monetize pharma

Every major EHR vendor — Epic, Oracle Cerner, athenahealth, Veradigm, NextGen, eClinicalWorks — runs a partner program. The name varies (App Orchard, Business Partner Program, Marketplace, Partner Network), but the commercial mechanism is the same: the EHR sells a structured set of data products or integration access to vendors, and the vendors sell services downstream to pharma, medical-device, and life-sciences buyers.

If you work in pharma marketing or activation, you’ve probably bought from one of these programs indirectly — through an SMS-at-prescription vendor, an HCP media network, or a programmatic pharma DSP. The vendors you contract with are paying the EHR partner program for access. They’re the visible layer. The commercial engine underneath is the partner program.

The three-sided economics

There are three parties in every EHR-partner-program transaction:

• The EHR partner program. Owns aggregate reporting surface area. Wants incremental revenue without changing the clinical workflow or adding new data surfaces.
• The activation vendor. Buys access to the partner program’s reporting. Uses it to size campaigns, target HCPs, or run activation. Pays the partner program a revenue share.
• The pharma buyer. Pays the activation vendor for a promotional campaign. Doesn’t typically contract directly with the EHR.

The partner program collects margin from the activation vendor. The activation vendor collects margin from pharma. Pharma pays for a campaign that reaches their target HCPs inside the clinical workflow.

What the partner program actually sells

Three broad categories, depending on the EHR:

• In-workflow activation. Messaging that reaches the clinician inside their EHR — typically tied to prescribing decisions (SMS at prescription, co-pay offer at point of Rx, banner in the medication-reconciliation workflow). This is the biggest category and the one with the highest ACVs.
• Out-of-workflow activation. Email, direct mail, HCP media networks. Uses the partner program’s HCP list for targeting but reaches them outside the clinical moment.
• Aggregate analytics. Research and planning data — cohort sizes, prescribing trends, specialty coverage. Usually licensed as a data product without any activation path attached.

The friction pharma marketers actually feel

Three frustrations are universal across the pharma marketers we talk to:

• Fragmentation. Every EHR has its own partner program, its own activation vendors, its own contract shape. A pharma brand that wants to reach 80% of US cardiologists has to triangulate across five to eight different vendors.
• Opaque sizing. Before you commit to a $250k activation, you want to know what the addressable universe actually looks like. Most vendors will tell you after you’ve engaged. Few will tell you up front.
• No neutral view. Every vendor is selling their footprint. Nobody is incentivized to show you where theydon’t have coverage, even though that’s exactly what you need to make the buy-vs-skip decision.

Where a neutral broker fits

That friction is why “neutral broker” is a legitimate category — not an aspirational positioning. A broker that sits between the partner programs and the pharma buyer, sources demand, qualifies it against the full network, and routes signed deals onto the partner program’s standard paper solves the fragmentation and the sizing problem at once.

The broker doesn’t need to host data, build ad surfaces, or take the pharma contract. Those are all jobs the existing ecosystem does well. The broker’s job is to compose the view: what’s the addressable universe here, across whose network, for which campaign. Once that’s answered, the activation contract slots back onto the partner program’s standard paper and the campaign runs through the vendor’s existing rails.

That’s the thesis behind Scriptlane. We’re the composition layer. We don’t touch PHI. We don’t host data at rest. We take the pharma relationship load off the partner program and the sourcing load off the activation vendor. Revenue flows the same way it would have, minus our referral commission.

What to do with this

If you’re a pharma marketer: next time you’re evaluating an activation vendor, ask what partner program they pay into and what their footprint looks like against your target brief. If they can’t give you aggregate numbers in under a week, that’s a yellow flag. If you’d rather just size it yourself first and then bring a qualified target to a vendor, scope it on Scriptlane before you start the RFP.

If you’re running an EHR partner program: you already know your channel volume is capped by the pharma demand your vendors can source, not by your network coverage. A broker that specializes in sourcing and qualification — and contracts onto your standard paper — is pure incremental revenue at zero operational load.